Linked Life Data

2915860

Source:http://linkedlifedata.com/resource/pubmed/id/2915860

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3 Pt 1
pubmed:dateCreated
1989-3-23
pubmed:abstractText
A chemotherapeutic combination consisting of VM-26-vincristine-cisplatin was used to treat 44 consecutive patients with primary advanced or recurrent endometrial carcinomas. Nine complete remissions (20.5%) and 14 partial remissions (31.8%) were recorded. The median duration of remission in responders was 8 months (range 1-35). The responding patients had significantly longer survival than nonresponders. The median duration of survival in the complete series was 7 months. The response rates and survival times were the same for primary advanced tumors and recurrences, regardless of sites. Peripheral neuropathy, secondary anemia, and nausea were the most common side effects. The drug combination was well tolerated, and its efficacy is comparable to that of other more toxic chemotherapy regimens.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0029-7844
pubmed:author
pubmed:issnType
Print
pubmed:volume
73
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
343-8
pubmed:dateRevised
2009-10-26
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
VM-26-vincristine-cisplatin combination chemotherapy in the treatment of primary advanced and recurrent endometrial carcinoma.
pubmed:affiliation
Department of Gynecologic Oncology, Orebro Medical Center, Regionsjukhuset, Sweden.
pubmed:publicationType
Journal Article